InvestSMART

Emyria Limited (ASX: EMD) - Announcements

- Current share price for EMD : $0.032

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$26 Notification of cessation of securities - EMD 23 Aug 2023 5:02PM $0.090 $0.032 fallen by 64.44%
$26 Notification regarding unquoted securities - EMD 23 Aug 2023 5:00PM $0.090 $0.032 fallen by 64.44%
$26 Emyria Announces Strategic Board Transition 21 Aug 2023 8:41AM $0.093 $0.032 fallen by 65.59%
$26 Change of Director's Interest Notice - A. Vickery 11 Aug 2023 12:48PM $0.097 $0.032 fallen by 67.01%
$26 Change of Director's Interest Notice - S. Washer 10 Aug 2023 8:15AM $0.095 $0.032 fallen by 66.32%
$26 Change of Director's Interest Notice - M. Winlo 9 Aug 2023 8:23AM $0.087 $0.032 fallen by 63.22%
$26 Emyria Launches Ketamine-Assisted Therapy Program 8 Aug 2023 9:37AM $0.097 $0.032 fallen by 67.01%
$26 June 2023 Quarterly Activities Report and Appendix 4C 31 Jul 2023 10:20AM $0.110 $0.032 fallen by 70.91%
$26 Emyria Recruits First Patient MDMA-Assisted Therapy Trial 10 Jul 2023 8:15AM $0.145 $0.032 fallen by 77.93%
$26 Presentation - Pax Acquisition and Company Update 6 Jul 2023 9:34AM $0.140 $0.032 fallen by 77.14%
$26 Proposed issue of securities - EMD 3 Jul 2023 9:47AM $0.125 $0.032 fallen by 74.40%
$26 Pax Centre Acquisition to Advance Psychedelic Therapies 3 Jul 2023 9:47AM $0.125 $0.032 fallen by 74.40%
$26 Trading Halt 29 Jun 2023 9:33AM $0.125 $0.032 fallen by 74.40%
$26 Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 Jun 2023 9:10AM $0.125 $0.032 fallen by 74.40%
$26 Section 708A(5)(e) Notice 10 May 2023 6:37PM $0.150 $0.032 fallen by 78.67%
$26 Application for quotation of securities - EMD 10 May 2023 6:26PM $0.150 $0.032 fallen by 78.67%
$26 Notification regarding unquoted securities - EMD 10 May 2023 6:22PM $0.150 $0.032 fallen by 78.67%
$26 Proposed issue of securities - EMD 1 May 2023 10:07AM $0.170 $0.032 fallen by 81.18%
$26 Emyria Completes $2.5m Placement 1 May 2023 10:07AM $0.170 $0.032 fallen by 81.18%
$26 March 2023 Quarterly Activities Report and Appendix 4C 28 Apr 2023 2:34PM $0.170 $0.032 fallen by 81.18%
$26 Trading Halt 27 Apr 2023 9:24AM $0.170 $0.032 fallen by 81.18%
$26 Emyria Unveils Highest Potency CBD Capsule for FDA Pathway 24 Apr 2023 9:25AM $0.170 $0.032 fallen by 81.18%
$26 Emyria to Develop Psilocybin Therapy Care Model 18 Apr 2023 8:15AM $0.165 $0.032 fallen by 80.61%
$26 Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5 4 Apr 2023 8:53AM $0.190 $0.032 fallen by 83.16%
$26 Strong Recruitment for EMD-RX5 Phase 3 Trial 23 Mar 2023 8:16AM $0.175 $0.032 fallen by 81.71%

276 - 300 of 583 results

Page 12 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.